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Despite a well-defined role for the Fanconi anemia (FA) pathway in mediating DNA repair, the mechanisms
underlying the bone marrow failure in FA patients are poorly defined. Recently in Nature, Garaycoechea
et al. (2012), identify aldehyde-mediated genotoxicity of hematopoietic stem cells as a cause for bonemarrow
failure.Exposure to exogenous or endogenous
genotoxic agents (e.g., radiation, muta-
genic agents, endogenous reactive meta-
bolites) has deleterious consequences
on cells in the bone marrow, often leading
to anemia, cancer, and cellular aging. In
general, long-lived quiescent hematopoi-
etic stemcells (HSCs) canundergogrowth
arrest and thereby survive genotoxic
stress, whereas proliferating progenitors
andmature blood cells undergo apoptosis
and die. Nevertheless, DNA damage and
genomic instability from genotoxic stress
can accumulate in the surviving HSCs,
which can be detrimental during their life
span. The genotoxins that cause the dele-
terious DNA damage and the protective
mechanisms that operate to repair this
damage in the HSCs are poorly defined.
Recently, a few specific DNA repair mech-
anisms, operative in HSCs, have been
identified (Niedernhofer, 2008).
Endogenous aldehydes, produced
during normal cellular metabolism, are
known to be carcinogenic. Whether these
normal metabolites also represent a
specific genotoxic burden for HSCs
remains unknown. A recent study pub-
lished in Nature (Garaycoechea et al.,
2012) from K.J. Patel’s laboratory demon-
strates that endogenous aldehydes are
indeed genotoxic to HSCs and that
HSCs have a novel mechanism of protec-
tion from this DNA damage. Specifically,
endogenous aldehydes pose a severe
threat to normal HSCs in the absence of
two important protective elements:
namely, the Fanconi anemia (FA) DNA
repair pathway and the enzyme aldehyde
dehydrogenase 2 (Aldh2).
The FA pathway consists of a network
of at least 15 proteins that cooperate in
the repair of DNA interstrand crosslinks(reviewed in Kim and D’Andrea, 2012).
The pathway was established through
the systematic study of families with the
rare genetic disease Fanconi anemia,
which is characterized by progressive
bonemarrow failure (due to HSC attrition),
developmental abnormalities, heightened
susceptibility to cancer (especially late
developing myeloid malignancies), and
cellular hypersensitivity to interstrand
DNA crosslinkers. Increased chromo-
somal breakage and chromosome radials
following exposure to DNA crosslinking
agents, such as Cisplatin, is the cellular
hallmark of FA.
Mouse models for FA have been gener-
ated through genetic disruption of several
of the FA genes, including Fancc, Fanca,
Fancl, Fancd2, Fancd1/Brca2, and
Fancp/Slx4. While mice with a genetic
deficiency in the FA pathway exhibit
cellular hypersensitivity to interstrand
crosslinking agents, they do not develop
spontaneous bone marrow failure (Par-
mar et al., 2009), with the exception of
the Fancp/Slx4 mice (Crossan et al.,
2011), thus hampering pathogenesis
studies of this disease. Due to the well-
studied role of FA proteins in DNA cross-
link repair, it was predicted that the
cellular DNA repair defect is the main
cause of the FA disease. Still, the nature
of the endogenous crosslinking agent re-
mained unknown. A breakthrough came
last year when the Patel laboratory
discovered that endogenous reactive
aldehydes are the genotoxins that are
largely responsible for the pathophysi-
ology of FA (Langevin et al., 2011).
Patel and colleagues had previously
shown that FA pathway-deficient chicken
DT-40 cells, as well as murine bone
marrow hematopoietic cells, are hyper-Cell Stem Cell 11,sensitive to acetaldehyde, a by-product
of natural metabolism (Langevin et al.,
2011). Using genetic mouse models,
these investigators elegantly showed
that FA pathway counteracts the toxic
effects of acetaldehydes in mice. Mice
with combined deficiency in one of the
FA genes (Fancd2) and Aldh2 (an enzyme
that catabolizes acetaldehyde into
acetate) displayed developmental defects
and succumbed to acute leukemia
within 3–6 months after birth. Moreover,
these double knockout (KO) mice were
highly susceptible to the toxic effects of
ethanol—an exogenous source of acetal-
dehyde, and ethanol exposure induced
bonemarrow failure in thesemice. Collec-
tively, these findings indicated that acetal-
dehyde-mediated toxicity may contribute
to the pathogenesis of FA.
In order to more precisely dissect the
role of the FA pathway in acetaldehyde-
mediated bone marrow failure, the Patel
laboratory further analyzed the untreated
Fancd2/ Aldh2/ mice for hematopoi-
etic defects (Garaycoechea et al., 2012).
While most of the double KO animals
succumbed to leukemia as they aged,
the surviving mice developed low blood
cell counts. In addition, a small per-
centage of the older mice without
leukemia (6/29) exhibited aplastic anemia,
which is a hallmark feature of human FA
and is characterized by a pantocytopenia,
hypocellular bone marrow, and extra-
medullary hematopoiesis. Interestingly,
the clinical phenotypes of Fancd2/
Aldh2/ mice correlated with increased
DNA damage (gamma H2AX positive
cells) and apoptosis in the bone marrow.
Strikingly, the DNA damage response
was more profound in the hematopoietic
stem and progenitor (HSPC) populations,November 2, 2012 ª2012 Elsevier Inc. 583
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Figure 1. Acetaldehyde, an Endogenous Aldehyde, Poses a Severe
Threat to HSCs in the Absence of Aldh2 Enzyme and a Functional
Fanconi Anemia Pathway
Acetaldehyde is normally generated during natural cellular metabolism and is
detoxified by aldehyde dehydrogenase enzymes. For instance, Aldh2 enzyme
converts toxic acetaldehyde into acetate. When Aldh2 is not functional, acet-
aldehyde accumulates and causes DNA damage in HSCs. The Fanconi
anemia (FA) DNA repair pathway protects the HSCs from this genotoxic
stress. In the absence of both Aldh2 and a functional FA pathway, HSCs
struggle for existence, leading to bone marrow failure and leukemia.
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Previewsincluding the long-termHSCs
(LT-HSCs), than in the other
progenitor populations of the
bone marrow. These results
suggested that perhaps the
genotoxic lesions from the
acetaldehyde catabolism
preferentially occur in the
HSCs and are repaired by
the FA proteins. To confirm
this, the authors systemati-
cally evaluated several bone
marrow cell populations for
acetaldehyde sensitivity by
exposing the cells in vitro.Un-
expectedly, they found that
only HSPCs, and not the
mature blood cells or colony-
forming progenitors, require
both Aldh2 and FA pathway
for protection against alde-
hyde toxicity. Consistent with
these observations, aldehyde
dehydrogenase activity ofHSPCs was mostly due to the Aldh2.
The investigators next confirmed the
requirement of both the FA pathway and
Aldh2 against the genotoxicity of acetal-
dehyde in HSCs by using the young
(8- to 12-week-old) Fancd2/ Aldh2/
mice (Garaycoechea et al., 2012). These
mice had not developed leukemia or
bone marrow failure. The immunopheno-
typing analysis of the bone marrow
showed a marked reduction in the HSPC
and LT-HSC populations, with almost
250-fold reduction in the frequency of
SLAM-expressing LT-HSCs compared to
the wild-type littermates or single KO
mice. Furthermore, the LT-HSCs from
the double KO mice were less quiescent
and more actively cycling. The HSCs
from the double KOmice were also tested
functionally in bone marrow transplanta-
tion experiments. Strikingly, the bone
marrow from the double KO mice was
severely compromised in the long-term
repopulation ability with 638-fold reduc-
tion in competitive repopulating units,
compared to wild-type bone marrow.
Aldh2/ bone marrow and Fancd2/
bone marrow exhibited only 2.75-fold
and 38-fold reduction (Parmar et al.,
2010; Zhang et al., 2010), respectively.
Taken together, these observations
confirmed that combined deficiency of
both the FA pathway and acetaldehyde
catabolism can lead to profound HSC
defects in the bone marrow (Figure 1).584 Cell Stem Cell 11, November 2, 2012 ª2The HSC attrition results in bone marrow
failure or leukemia. These studies there-
fore suggest that the progression of bone
marrow failure in FA is perhaps due to the
aldehyde-mediated genotoxicity in HSCs.
The findings by Patel’s group highlight
the importance of a functional FA pathway
in resolving the cellular damage caused
by endogenous aldehydes in HSCs
and enhance our understanding of mech-
anisms for HSC loss in FA patients.
Recent studies from our own laboratory,
in collaboration with the Soulier group,
using primary FA patient bonemarrow, re-
vealed that an exacerbated p53/p21
response caused by cellular stress and
DNA damage in HSPCs may cause bone
marrow failure in FA (Ceccaldi et al.,
2012). HSPC depletion in FA starts during
fetal development, due to the hyperacti-
vation of the p53/p21 axis, perhaps
caused by replicative stress and in-
creased DNA damage. Taken together,
the hyperactivation of p53/p21 response
observed in FA fetal liver cells and bone
marrow HSPCs may be due, at least in
part, to an aldehyde-mediated endoge-
nous DNA damage mechanism. Besides
the DNA damage caused by aldehydes,
additional injury caused by inflammatory
cytokines (e.g., TNF-alpha) or oxidative
stress may also lead to dysfunctional
HSCs in the FA bone marrow.
These new studies by Patel’s group
may lead to the identification of new ther-012 Elsevier Inc.apies for the bone marrow
failure in FA. For instance,
agents that can enhance the
catabolism of endogenous
aldehydes (e.g., agonists of
Aldh2) may provide a new
therapeutic avenue. The
Fancd2/ Aldh2/ double
KO mice may serve as a valu-
able model for testing new
therapies for FA because
they recapitulate the bone
marrow failure and other
pathophysiological features
observed in FA patients.
Several outstanding ques-
tions remain. We still do not
know (1) which specific alde-
hyde in stem cells of FA is
the most toxic, (2) the nature
of the genotoxic stress (i.e.,
is it a DNA or protein cross-
link?), or (3) how the damage
ultimately weakens HSCs.Nevertheless, these recent discoveries
from the Patel laboratory provide impor-
tant insights into the mechanisms of gen-
otoxin defense in HSCs and into the
underlying nature of bone marrow failure
in FA.
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